Frederick Robbins Taylor

USPTO Granted Patents = 18 (Patent Applications = 13)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 4.0

ph-index = 7

Forward Citations = 220(Granted Patents)

Location History:

Gainesville, FL (US) (1998 - 1999)
Milton, MA (US) (2002 - 2024)

Company Filing History:

9. 2 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...

18 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11879008 - Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator (2024-01-23),

2. 11571477 - Anti-VLA-4 antibodies (2023-02-07),

3. 11083791 - Anti-VLA-4 antibodies (2021-08-10),

4. 11053306 - Fusion protein constructs comprising anti-C3d antibody and factor H (2021-07-06),

5. 11053305 - Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptide (2021-07-06),

6. 10335485 - Anti-VLA-4 antibodies (2019-07-02),

7. 9902775 - Anti-blood dendritic cell antigen 2 antibodies and uses thereof (2018-02-27),

8. 9738707 - Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto (2017-08-22),

9. 9321840 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2016-04-26),

10. 8784823 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2014-07-22),

11. 8318917 - Nucleic acids encoding antibodies having altered effector function and methods for making the same (2012-11-27),

12. 8293237 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2012-10-23),

13. 7863419 - Antibodies having altered effector function and methods for making the same (2011-01-04),

14. 7479539 - Hedgehog fusion proteins (2009-01-20),

15. 6897297 - Hydrophobically-modified protein compositions and methods (2005-05-24),

Title: Frederick Robbins Taylor: Innovator in Complement-Mediated Disease Treatments

Introduction

Frederick Robbins Taylor, based in Milton, MA, is a renowned inventor known for his significant contributions to the field of biomedical innovation. With a total of 18 patents to his name, his work focuses on advancing methods related to complement-mediated diseases, showcasing his dedication to improving patient outcomes through cutting-edge research and development.

Latest Patents

Among his latest innovations is a patent titled "Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator." This invention presents fusion protein constructs capable of binding to complement-associated antigens, utilizing a targeting moiety, which may consist of an antibody or an antigen-binding fragment. The applications of these constructs are particularly focused on treating conditions that involve complement mediation, representing a significant advancement in therapeutic strategies.

Another notable patent involves "Anti-VLA-4 antibodies," which pertains to alpha-4 binding antibodies and their corresponding fragments. This development is crucial for various therapeutic applications, enhancing the understanding of immune response modulation.

Career Highlights

Frederick Taylor has worked with several prominent companies in the biotechnology sector, including Biogen MA Inc. and Biogen Idec MA Inc. His extensive experience in these organizations has enabled him to leverage his scientific expertise and translate it into valuable innovations within the pharmaceutical industry.

Collaborations

Throughout his career, Taylor has collaborated with esteemed professionals like Ellen A. Garber and Justin Andrew Caravella. These partnerships have contributed greatly to the advancement of his research and innovations, fostering a collaborative environment that encourages the exchange of ideas and expertise.

Conclusion

Frederick Robbins Taylor stands out as a pivotal figure in the realm of biomedical inventions, particularly in the treatment of complement-mediated diseases. His impressive portfolio of patents and collaborations underscores his commitment to innovation in healthcare, making notable strides towards developing more effective therapies for patients in need.

This text is generated by artificial intelligence and may not be accurate.